TPT has developed a unique novel technology for enhancement of bioavailability of Class II and Class IV drugs which are otherwise poorly bioavailable due to solubility and or permeability limitations. The technology is amenable to adapt in any type of oral dosage forms. The technology is simple and easy to scale up. TPT is currently using this platform technology to develop dosage forms for different important drug molecules used in the treatment of hormone replacement therapy, treatment of HIV infection and antifungal treatment.
TPT LLC Received A Research Grant From USFDA
TPT LLC received a U01 research grant from USFDA to perform researchonImpact of Formulation Composition on the Structure and Performance Attributes of Topical Products. ( (1U01FD006507-01).
TPT LLC Works In Collaboration With Certara On A Research Grant Funded By USFDA
TPT LLC in collaboration with Certara, UK has received a two-year funding to conduct research on the BA/BE simulation of topical products.
